{"id":821703,"date":"2025-03-04T16:33:56","date_gmt":"2025-03-04T21:33:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-therapeutics-announces-investor-webinar-to-discuss-positive-interim-data-from-phase-i-ii-allocetra-trial-in-knee-osteoarthritis\/"},"modified":"2025-03-04T16:33:56","modified_gmt":"2025-03-04T21:33:56","slug":"enlivex-therapeutics-announces-investor-webinar-to-discuss-positive-interim-data-from-phase-i-ii-allocetra-trial-in-knee-osteoarthritis","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-therapeutics-announces-investor-webinar-to-discuss-positive-interim-data-from-phase-i-ii-allocetra-trial-in-knee-osteoarthritis\/","title":{"rendered":"Enlivex Therapeutics Announces Investor Webinar to Discuss Positive Interim Data from Phase I\/II Allocetra\u2122 Trial in Knee Osteoarthritis"},"content":{"rendered":"
\n

Ness-Ziona, Israel, March 04, 2025 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company,\u00a0is pleased to invite investors to a live investor webinar on March 5, 2025, at 11:00 a.m. ET to discuss the positive interim six-month data from the Phase I stage of its ongoing randomized, multi-country Phase I\/II Allocetra\u2122 trial in patients with moderate to severe knee osteoarthritis.<\/p>\n

The exclusive event, hosted by RedChip Companies, will feature the Company\u2019s Chief Executive Officer, Oren Hershkovitz Ph.D., who will provide a detailed review of the interim results, which demonstrated a statistically significant 47.0% average reduction in reported pain (P=0.0001) and a 46% improvement in joint function at six months post-treatment. Additionally, 83% of treated patients were still considered responders to treatment at six months, which the Company believes highlights the durability and sustained efficacy of Allocetra\u2122 as a potential breakthrough treatment for osteoarthritis. Importantly, no serious adverse events were reported, reinforcing the favorable safety profile of Allocetra\u2122.<\/p>\n

Dr. Hershkovitz commented, \u201cWe are excited by these promising interim results, which showcase Allocetra\u2122\u2019s potential to deliver meaningful and sustained, pain relief for patients suffering from moderate to severe knee osteoarthritis. The consistency and durability of the efficacy data\u2014combined with the safety profile\u2014underscore Allocetra\u2122\u2019s promising potential to become a novel treatment in a space with urgent unmet medical needs. We remain deeply committed to advancing this innovative therapy and unlocking its full potential for millions of patients worldwide.\u201d<\/p>\n

\n Webinar Details<\/strong>\n <\/p>\n